A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Based on results from earlier clinical trials, Pemetrexed may have antitumor activity as a
first-line agent in the treatment of mesothelioma. Given this, it is hypothesized that
Pemetrexed may be active in second-line mesothelioma in which the standard treatment is best
supportive care. This study will compare survival of previously treated patients with
malignant pleural mesothelioma who receive Pemetrexed plus best supportive care to the
survival of similar patients who receive best supportive care alone.